SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Fundamental Analysis
Europe - BIT:1SRPT - US8036071004 - Common Stock
19.45 EUR
-0.98 (-4.8%)
Taking everything into account, 1SRPT scores 3 out of 10 in our fundamental rating. 1SRPT was compared to 76 industry peers in the Biotechnology industry. Both the profitability and financial health of 1SRPT have multiple concerns. 1SRPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
1SRPT had negative earnings in the past year.
1SRPT had a negative operating cash flow in the past year.
1SRPT had negative earnings in 4 of the past 5 years.
1SRPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.57%, 1SRPT is in the better half of the industry, outperforming 72.97% of the companies in the same industry.
1SRPT has a Return On Equity of -4.27%. This is in the better half of the industry: 1SRPT outperforms 74.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.57% | ||
| ROE | -4.27% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 79.28%, 1SRPT is in the better half of the industry, outperforming 72.97% of the companies in the same industry.
1SRPT's Gross Margin has been stable in the last couple of years.
1SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
1SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1SRPT has more shares outstanding
1SRPT has more shares outstanding than it did 5 years ago.
1SRPT has a better debt/assets ratio than last year.
2.2 Solvency
1SRPT has an Altman-Z score of 0.15. This is a bad value and indicates that 1SRPT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of 1SRPT (0.15) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.84 indicates that 1SRPT is somewhat dependend on debt financing.
1SRPT has a Debt to Equity ratio (0.84) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.15 |
ROIC/WACCN/A
WACC6.86%
2.3 Liquidity
A Current Ratio of 2.89 indicates that 1SRPT has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.89, 1SRPT is doing good in the industry, outperforming 63.51% of the companies in the same industry.
1SRPT has a Quick Ratio of 1.81. This is a normal value and indicates that 1SRPT is financially healthy and should not expect problems in meeting its short term obligations.
1SRPT has a Quick ratio (1.81) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The earnings per share for 1SRPT have decreased strongly by -293.33% in the last year.
1SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.89%.
The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
3.2 Future
Based on estimates for the next years, 1SRPT will show a small growth in Earnings Per Share. The EPS will grow by 7.30% on average per year.
1SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.18% yearly.
EPS Next Y-295.33%
EPS Next 2Y2.29%
EPS Next 3Y2.17%
EPS Next 5Y7.3%
Revenue Next Year9.27%
Revenue Next 2Y-7.68%
Revenue Next 3Y-7.58%
Revenue Next 5Y-5.18%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
1SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
1SRPT is valuated reasonably with a Price/Forward Earnings ratio of 9.42.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SRPT indicates a rather cheap valuation: 1SRPT is cheaper than 97.30% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.27, 1SRPT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.42 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SRPT is valued a bit cheaper than 75.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 59.83 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.29%
EPS Next 3Y2.17%
5. Dividend
5.1 Amount
No dividends for 1SRPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1SRPT (10/22/2025, 7:00:00 PM)
19.45
-0.98 (-4.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.76%
Inst Owner ChangeN/A
Ins Owners4.63%
Ins Owner ChangeN/A
Market Cap2.04B
Revenue(TTM)2.48B
Net Income(TTM)-57956000
Analysts67.43
Price Target28.32 (45.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-5.92%
EPS NQ rev (3m)-1852.02%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-6.79%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)-32.18%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)-8.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.42 | ||
| P/S | 0.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.73 | ||
| P/tB | 1.77 | ||
| EV/EBITDA | 59.83 |
EPS(TTM)-0.75
EYN/A
EPS(NY)2.06
Fwd EY10.62%
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-2.49
OCFYN/A
SpS20.52
BVpS11.22
TBVpS10.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.57% | ||
| ROE | -4.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.28% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 28.38 | ||
| Cap/Depr | 372.98% | ||
| Cap/Sales | 6.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 0.15 |
F-Score2
WACC6.86%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
EPS Next Y-295.33%
EPS Next 2Y2.29%
EPS Next 3Y2.17%
EPS Next 5Y7.3%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
Revenue Next Year9.27%
Revenue Next 2Y-7.68%
Revenue Next 3Y-7.58%
Revenue Next 5Y-5.18%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / 1SRPT.MI FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?
ChartMill assigns a fundamental rating of 3 / 10 to 1SRPT.MI.
What is the valuation status of SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?
ChartMill assigns a valuation rating of 3 / 10 to SAREPTA THERAPEUTICS INC (1SRPT.MI). This can be considered as Overvalued.
Can you provide the profitability details for SAREPTA THERAPEUTICS INC?
SAREPTA THERAPEUTICS INC (1SRPT.MI) has a profitability rating of 2 / 10.
What is the expected EPS growth for SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?
The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (1SRPT.MI) is expected to decline by -295.33% in the next year.